Author

T. Gujral

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Research Focus:gene regulatory network inference· 2 Assay:proteomics· 2

Frequent Co-Authors

A. R. Farghli· 2 shared M. Chan· 2 shared M. Nukaya· 2 shared P. Sethupathy· 2 shared A. Arakaki· 1 shared A. Folch· 1 shared A. J. Shumway· 1 shared A. Yen· 1 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. R. Farghli

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma

R. K. Ma, P.-Y. Tsai, A. R. Farghli, A. J. Shumway, M. Kanke, J. D. Gordan, T. Gujral, K. Vakili, M. Nukaya, L. Noetzli, S. Ronnekleiv-Kelly, W. Broom, J. Barrow, P. Sethupathy

This paper identifies LINC00473 as a downstream mediator of DNAJB1-PRKACA fusion in fibrolamellar carcinoma, showing it promotes tumor growth and alters mitochondrial function.

bioRxiv · Jun 2, 2023Cancer Biology

CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma

M. Nukaya, C. Cafferty, K. Zahed, I. Yun, D. P. Al-Adra, N. A. Kazim, A. R. Farghli, M. Chan, J. D. Kratz, M. E. Berres, A. Yen, T. Gujral, P. Sethupathy, C. A. Bradfield, S. M. Ronnekleiv-Kelly

This study identifies CDK7 as a therapeutic target in fibrolamellar carcinoma by showing its activation in FLC cells and efficacy of CDK7 inhibitors in patient-derived models.

bioRxiv · Apr 22, 2023 · PreprintCancer Biology

A 96-WELL VALVED MICROFLUIDIC DEVICE FOR TESTING OF LIVE INTACT TUMOR CUBOIDS

E. Lockhart, L. F. Horowitz, C. Lim, T. Nguyen, M. Mehrabi, T. Gujral, A. Folch

The paper introduces a 96-well microfluidic device for testing drug responses in live tumor cuboids, preserving the tumor microenvironment for personalized oncology applications.

bioRxiv · Jul 7, 2022 · PreprintBioengineering

Both YAP1-MAML2 and constitutively active YAP1 drive the formation of tumors that resemble NF2-mutant meningiomas in mice

F. Szulzewsky, S. Arora, A. Arakaki, P. Sievers, D. A. A. Bonnin, P. J. Paddison, F. Sahm, P. J. Cimino, T. Gujral, E. C. Holland

This study shows that YAP1-MAML2 and active YAP1 drive tumors resembling NF2-mutant meningiomas in mice through TEAD-dependent YAP activity.

bioRxiv · May 2, 2022 · PreprintCancer Biology

Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release

M. Chan, E. Holland, T. Gujral

This paper shows that Olverembatinib inhibits cytokine release caused by the SARS-CoV-2 Omicron variant in human PBMCs, suggesting it as a potential treatment for severe COVID-19.

bioRxiv · Feb 7, 2022 · PreprintImmunology